Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2Thoracic 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Sarcoma, Ewing 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Eflornithine × Sarcoma × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT06892678 2026-05-14

DFMO

Montefiore Medical Center

Phase 1/2 Recruiting
15 enrolled
Sarcoma

Osteosarcoma Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡